02853nas a2200337 4500000000100000008004100001260002300042653001500065653002700080653001400107653001200121653001400133653001500147653001100162653001100173100000900184700001200193700001000205700001100215700001000226700001000236700001100246700000900257700001100266245005000277856008900327300001400416490001400430520205700444022001402501 2023 d bInforma UK Limited10aImmunology10aImmunology and Allergy10aPsoriasis10aLeprosy10aTh17 cell10amacrophage10aIL-17A10aCLEC4E1 aGe G1 aShang J1 aGan T1 aChen Z1 aPan C1 aMei Y1 aLong S1 aWu A1 aWang H00aPsoriasis and Leprosy: An Arcane Relationship uhttps://www.tandfonline.com/doi/epdf/10.2147/JIR.S407650?needAccess=true&role=button a2521-25330 vVolume 163 a
Purpose: Psoriasis (Ps) and leprosy are chronic inflammatory skin disorders, characterised by enhanced innate and adaptive immunity. Ps and leprosy rarely coexist. The molecular immune mechanism of the Ps and leprosy rarely coexistence is unclear.
Patients and Methods: RNA-sequencing (RNA-seq) was performed on 20 patients with Ps, 5 adults with lepromatous leprosy (L-lep), and 5 patients with tuberculoid leprosy (T-lep) to analyse the differentially expressed genes (DEGs) between them. Moreover, the biological mechanism of Ps and leprosy was explored by Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis, Gene Ontology (GO) analysis, Gene Set Enrichment Analysis analysis, and protein–protein interaction (PPI) analyses. Finally, 13 DEGs of 10 skin biopsies of Ps patients, 6 samples of L-lep patients, 6 samples of T-lep patients and 5 healthy controls were confirmed by quantitative real-time polymerase chain reaction (qRT-PCR).
Results: The PPI network was constructed and primarily associated with immune response, IL-17 signalling, and Toll-like receptor pathway between Ps and leprosy. Th17 markers (interleukin (IL)-19, IL-20, IL-36A, IL-36G, IL-22, IL-17A, and lipocalin-2 (LCN2) had higher expression in Ps than in L-lep and T-lep, whereas macrophage biomarkers (CLEC4E and TREM2), SPP1, and dendritic cell (DC)-related hallmarks (ITGAX) and TNF-a had significantly lower expression across Ps and T-lep than in L-lep.
Conclusion:
To put it simply, Ps patients with IL-17A, IL-19, IL-20, IL-36A, IL-36G, and IL-22 in conjunction with LCN2 with up-graduated expression might be not susceptible to L-lep. However, high levels of CLEC4E, TREM2, and SPP1 in L-lep patients indicated that they unlikely suffered from Ps.
a1178-7031